Market Overview

Anti-VEGF Antibodies Markets 2017-2022: Global Technology Assessment, Market Analysis and Future Growth Trends Report 2018 -


The "Anti-VEGF
Antibodies: Global Technology Assessment, Market Analysis and Future
Growth Trends"
report has been added to's

Due to rapid advancements in genetic sequencing and the translation of
basic medical sciences research into clinical practice, humanized mAbs
have turnout to be fastest growing group of biotechnology-derived
molecules in clinical trials. Driven by the growing application area
pertaining to target disease viz. cancers, autoimmune disorders,
infectious diseases, the monoclonal antibody market was valued over US$
100 billion in 2017 and is forecast to grow at a double digit Compound
Annual Growth Rate (CAGR) by year 2023.

Although various small molecule kinase inhibitors have been approved for
targeting VEGF induced signaling, but the use of mAbs against VEGF have
been established since FDA approval of Bevacizumab (Avastin,
Genentech/Roche) in year 2004. Since, Avastin, FDA has approved
ranibizumab (Lucentis, Genentech/Roche) and aflibercept (Eylea,
Regeneron Pharma) both for cancer treatment and age related macular
degradation (AMD). Therefore, use of mAbs in targeting VEGF induced
angiogenesis in cancer, inflammation, arthritis and AMDs have tremendous
potential in near future.

The report includes following key insights:

  • In this report we discuss the novel technologies/methodologies used
    for production, purification, structural modifications and formulation
    of mAbs against VEGF ligands in various human pathologies using
    technology distribution based on IP analysis
  • The report highlights the significant trends in efficacy, limitations
    and patient survival rate anti-VEGF antibodies therapy based on data
    available for Avastin, Lucentis, Eylea, Vanucizumab, Brolucizumab and
  • This report showcases the competitive benchmarking of key industrial
    players like Roche, Sanofi, Novartis, Regeneron Pharma, AbbVie etc. in
    development of anti-VEGF antibodies from laboratory to clinical trials
  • Product search and market forecast for trends in anti-VEGF mAbs will
    be extensively described
  • The report will further include detailed description of anti-VEGF
    antibodies in clinical trials and their beneficial effects on targeted
    patients especially cancer and age related macular degradation,
    autoimmune diseases
  • Report includes driving factors influencing global anti-VEGF mAbs
    market for year 2017-2022
  • Detailed description of SWOT and PEST analysis in development of
    anti-VEGF antibody therapy.

Key industry players

  • Roche
  • Novartis
  • Sanofi
  • Regeneron
  • Bayer
  • AstraZeneca

Key Topics Covered:

1. Technology Overview

2. Anti-VEGF antibodies: Technology Segmentation

3. Anti-VEGF antibodies: Global IP Trends

4. Anti-VEGF antibodies: Different diseases targeted

5. Anti-VEGF antibody: White Space Analysis

6. Recent activities in development of anti-VEGF antibody

7. Anti-VEGF Antibody Technology Opinions from Experts

8. Anti-VEGF Antibody Technology Collaboration Insights

9. Strategies of Companies involved in development of Anti-VEGF antibody

10. Recent Anti-VEGF Antibody Product Developments

11. Global Trends Anti-VEGF Antibody Market

12. Global Anti-VEGF antibody development: Top Industrial Players

13. Anti-VEGF Antibody - Market Determinants

14. Anti-VEGF Antibody -Opportunity Vs. Restraints

15. Anti-VEGF Antibody: Strategic Analysis SWOT & PEST

16. Anti-VEGF Antibody Market Development (2017-2022)

17. Conclusion

Companies Mentioned

  • Roche
  • Novartis
  • Sanofi
  • Regeneron
  • Bayer
  • AbbVie
  • Zymeworks
  • Elan Pharma
  • Five Prime Therapeutics
  • Kymab Ltd
  • Pfizer
  • AstraZeneca
  • Boehringer Ingelheim

For more information about this report visit

View Comments and Join the Discussion!